Resumo

SOLIS CARTAS, Urbano  e  MARTINEZ LARRARTE, Jose Pedro. Therapeutic options to cytokine release syndrome in patients with COVID-19. Rev Cub Med Mil [online]. 2020, vol.49, n.3  Epub 25-Nov-2020. ISSN 1561-3046.

Without doubt, COVID-19 has attracted the attention of the world population during the year 2020. The rapid spread of the disease, as well as the number of infections, complications and deaths, constitute the main distinctive elements of the disease. The inflammatory process, given by a high production of proinflammatory cytokines, forms the basis of respiratory complications. The objective of this work is to publicize the therapeutic options available to treat cytokine release syndrome. In this sense, it is important to highlight that biological drugs such as tocilizumab, anakinra and roxulitinib, as well as glucocorticoids, intravenous immunoglobulins and some immunosuppressants such as cyclosporin A, are therapeutic options, with theoretical options to combat the inflammatory process in seriously ill patients and which have shown encouraging results in the course of the global health crisis caused by COVID-19. It is concluded that there are therapeutic options to face the storm of proinflammatory cytokines that characterize this syndrome, observed in critically ill patients with this disease. It is now a challenge for scientists and health professionals to identify the right time for therapeutic indications and the algorithm of use, depending on the characteristics of the clinical picture and the patient's health conditions.

Palavras-chave : COVID-19; glucocorticoids; inflammation; immunoglobulin's;immunosuppressant's; biological therapy.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )